HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat - Wikidata - awgldk - TriplyDB

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

http://www.wikidata.org/entity/Q34106191

about

Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs Manipulation of the host protein acetylation network by human immunodeficiency virus type 1 Animal models in HIV cure research Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents Bioinformatics and HIV latency.Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations.Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay.Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.Framing expectations in early HIV cure research.Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo Translational challenges in targeting latent HIV infection and the CNS reservoir problem.Eradicating HIV-1 infection: seeking to clear a persistent pathogen.Genome editing strategies: potential tools for eradicating HIV-1/AIDS.HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation Activation and lysis of human CD4 cells latently infected with HIV-1 A Novel Class of HIV-1 Antiviral Agents Targeting HIV via a SUMOylation-Dependent Mechanism.Molecular mechanisms of HIV latency.Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.CRISPR-mediated Activation of Latent HIV-1 Expression A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy.Advances and hope for perinatal HIV remission and cure in children and adolescents.The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb.Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.

P2860

Q26781511-AD2965C6-428D-4A6B-A8A3-D197B1359FAF Q26795463-79D9C914-D580-4AAE-9C1E-E200B42CACAC Q26853069-4005179B-B9A4-47DA-8E73-C2858081203E Q28077662-D79A423D-FBD8-4337-A652-9B02D05DB82D Q28079455-A70823A5-D28E-491C-9B75-2F380E2A231A Q28081427-7160C5B1-6BF7-4B91-8713-7E4AFC47B85C Q28540858-BAB94506-48FA-46DA-BAAB-23B825951FFD Q28544949-00E976EB-D11C-443A-8614-54E7385761CE Q30490742-A632B817-91C4-4736-83BA-398395CF458C Q33627182-ED797471-BC0C-4B7E-842F-7E968589B484 Q33817708-C22DDCBE-B6E2-4C78-B4E9-1C516201D590 Q34180174-62DD69BC-90B5-4CC3-8F4A-6310C2B3AEB7 Q34363988-0DF0D7CF-DDF8-4E55-B4D6-9C18AA7D0A72 Q34596417-5C70078A-6C9D-4D34-BC5D-F56E56A6E127 Q34869380-FD33BA88-C412-4F4A-B296-C929D8B5DDFD Q35002986-E0A93E53-C14D-431F-AA67-369F57D7FBF1 Q35009744-560AD62B-75D3-4B55-9AAD-B06F7B734A70 Q35252186-3ED3684A-B5FD-4B23-A2A2-6803B0C832E1 Q35612053-5BA621DA-D50E-4615-AD84-92DFDDF70102 Q35680431-952849CC-69BA-4601-A7F9-72787551F45F Q35720063-BF3E56D2-F78A-497C-A847-19C961568D6F Q35778783-B3965099-888E-4013-AE95-B977917421E4 Q35819184-6D459B8A-6531-4B89-9711-7E026AAA8971 Q35973632-DD21761C-15D5-485E-A84B-CDED8B55C1F0 Q36030989-E67CF0F8-E7A1-42A3-91EB-DC1002224BDF Q36037844-49079282-CA0F-48F2-98A4-5CA5830F0CB9 Q36250921-52FA27A1-8D87-412A-9A61-5077033B3879 Q36353497-FA5D3105-8993-4EF2-A796-BB8B2A363D1B Q36515063-F41F0BCF-9C6B-486C-9DB9-67BD713F07CD Q36515149-92746085-1AB8-4A9B-9010-A5BBE62CE249 Q36523946-317842FB-AA91-485D-BBC8-47FA2DD68C5A Q36525896-54AD74E2-E874-4EEF-AFD7-F171C40C3A24 Q36538827-94512C23-C8C7-43EE-B3A3-D0A311DB8045 Q36596027-93DB8F48-6867-45D9-8AA2-9E6C909CFCFE Q36644877-4F2D1202-CB26-496A-B191-68C0F6C6E9B3 Q36675297-2EB56E1E-EEA9-406E-9ADE-3AE651AC08CA Q36736780-C0A02700-2CB6-4A86-AD05-C9E94830E154 Q36737063-2489064C-AE7D-4654-8665-23594C125F13 Q36790027-1E6DF2C4-150A-45C3-A186-5A587F0EFB15 Q37030360-77C51E5B-9468-4849-99E3-D54D49892E4E

P2860

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

http://www.wikidata.org/entity/Q34106191

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

@ast

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

@en

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

@nl

type

label

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

@ast

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

@en

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

@nl

prefLabel

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

@ast

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

@en

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

@nl

P1433

Q34106191-015A4843-0741-4EA8-AF28-9C77B64123AC

P1476

Q34106191-882AC700-BAB0-4FBE-A359-E1C4EA7EB2CF

P2093

Q34106191-25389B70-9846-4549-90CF-D7FFB93E18A7

Q34106191-27FAB620-487D-4E11-BC0D-1E6EF448FA40

Q34106191-422CE21D-63FB-4DD2-8349-DA083A631DD5

Q34106191-4A8870C1-6C50-4F58-A686-94FF3EEB10AD

Q34106191-7C5FC115-5EE7-456B-89B3-07CB34C17F36

Q34106191-7D06E629-BCC9-4B32-A2DA-1B1AD128A9EE

Q34106191-84B08F55-2971-4A55-9445-690A64873404

Q34106191-8F5DFFE5-C914-458E-8F51-5C25D7002295

Q34106191-9D0E78BC-CFF2-4BB6-9021-86EFC0C2D830

Q34106191-AD517BC5-6B86-4B33-99C8-1E7C9C34E6DC

P2860

Q34106191-02771410-68B0-49AF-A251-7E17FBAA2E45

Q34106191-094D4401-EAC7-4190-93F5-A74ACAAF804F

Q34106191-0A434611-D0A1-4373-9969-726C39921666

Q34106191-0CA41EEE-B13E-4F88-82E7-58CCE3776FED

Q34106191-15B3BEA3-A8D3-4FF0-A942-3DACCA60747A

Q34106191-22279CA8-D445-4244-B2C7-0B8FA82FB2E9

Q34106191-2AF92306-5B9E-4C63-B33E-2A56829A4C71

Q34106191-3F34CCB2-76E6-4F6E-90B1-570BD60A98BA

Q34106191-5825445D-32F4-4235-B9E0-8EABBDD06674

Q34106191-6407F7E7-3261-4152-8C85-CE599599F933

P304

Q34106191-323F331B-8D7B-4F13-85B6-B0A6F6181F06

P31

Q34106191-4C1B4250-F303-4007-860D-C8792C3F28DF

P356

Q34106191-3A5BA041-BFD5-4C83-848A-C4E74CCBC9BC

P407

Q34106191-DA9731BC-4F08-4F8E-A576-91FD7DD06E2B

P433

Q34106191-91BD8442-7BFA-4EC0-99C0-B1A659BF0475

P478

Q34106191-F6CCEE66-7D75-4203-AD77-93BDBA2C1EC6

P50

Q34106191-3C15BB9E-F4D9-4393-ADC8-40F58635A32B

Q34106191-50E54F97-5691-4464-AA09-9704C76C21DF

Q34106191-72ABFC3B-6052-40FB-BF3E-01E0EBE5F28B

Q34106191-92C14B52-0835-48F7-A54A-6008ECD804EF

P577

Q34106191-936C4971-D0EA-4D49-AEB0-5967AF05DD97

P5875

Q34106191-1E016E8F-AEBE-4CDB-959D-D143EC1180A6

P698

Q34106191-5EB2EBAC-461A-42D4-BD6D-1CC36F59D2FF

P932

Q34106191-7D83669C-02CF-4030-87F5-B12696A5B59F

P356

P1433

The Journal of Infectious Diseases

P1476

HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat

@en

P2093

Amanda M Crooks

http://www.w3.org/2001/XMLSchema#string

Angela D Kashuba

http://www.w3.org/2001/XMLSchema#string

Daria J Hazuda

http://www.w3.org/2001/XMLSchema#string

Douglas D Richman

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Anderson

http://www.w3.org/2001/XMLSchema#string

Joann D Kuruc

http://www.w3.org/2001/XMLSchema#string

John M Coffin

http://www.w3.org/2001/XMLSchema#string

Kevin R Robertson

http://www.w3.org/2001/XMLSchema#string

Kuo-Hsiung Yang

http://www.w3.org/2001/XMLSchema#string

Matthew C Strain

http://www.w3.org/2001/XMLSchema#string

P2860

The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

Eradication of HIV from the brain: reasons for pause

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

The survival benefits of AIDS treatment in the United States.

Highly precise measurement of HIV DNA by droplet digital PCR.

Histone deacetylase inhibitors and HIV latency.

P304

728-735

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIU155

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

210

http://www.w3.org/2001/XMLSchema#string

P50

David M. Margolis

Manoj K Tripathy

P577

2014-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260718684

http://www.w3.org/2001/XMLSchema#string

P698

24620025

http://www.w3.org/2001/XMLSchema#string

P932

4148603

http://www.w3.org/2001/XMLSchema#string